FDA approves Tetraphase's antibiotic Xerava
from BioPharma Dive
Big pharmas backed away from antibiotics in recent years, as the challenge of counteracting "superbugs" provided a tougher path to market. Earlier this year, for example, Allergan said it will sell off its infectious disease unit, which includes antibiotics. AstraZeneca sold its antibiotics portfolio in 2016, and Novartis reportedly exited the space earlier this year. That's left much of the space to smaller biotechs like Tetraphase.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063